Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: Provided are an acid addition salt of (+)-2-[(inden-7-yloxy)methyl]morpholine (compound A) and a novel crystal thereof, which are for use as a medicament or a drug substance, and which has high storage stability, particularly high stability against humidity and light. An acid addition salt of the compound A with an acid selected from benzenesulfonic acid and hydrobromic acid is a compound which is isolated in the form of a crystal, is a solid at room temperature, exhibits no hygroscopicity at such a level that causes a problem for use as a medicament or a drug substance, has stability against humidity and light, and is therefore extremely useful as a medicament or a drug substance.

Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenyleth-yl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: Novel crystals of a potassium salt of (E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide, a preparation process thereof, and novel solvates of (E)-N-[6-methoxy-5-(2-ethoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide.

Abstract: The 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide of the invention and its crystals, particularly ?- and ?- form Crystals, have no hygroscopic property, have excellent stability and therefore are useful as production materials of medicines. Particularly, the ?- form Crystal is most stable and markedly useful as a bulk for medicines.

Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenyleth-yl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: Novel crystals of a potassium salt of (E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide, a preparation process thereof, and novel solvates of (E)-N-[6-methoxy-5-(2-ethoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide.